SavedAdd your journal

Journals / Tüberküloz ve Toraks / 2003 / Cilt: 51 - Sayı: 1

Genetic risk factors of venous thromboembolism

Venöz tromboembolizmde kalıtsal risk faktörleri

Akın KAYA
Numan NUMANOĞLU
Ferda ÖNER
Ruşina DOĞAN
Pages
60–69
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This article focuses on the clinical and the laboratory aspects of some of the inherited venous thrombotic disorders including the factor V Leiden, prothrombin G20210A mutation and protein S deficiency.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Up to date several hereditary disorders have been identified as prothrombic risk factors.
📊
Key Findings & Data:The most common inherited thrombotic disorders include activated protein C resistance (factor V Leiden), prothrombin G20210A mutation, hyperhomocysteinemia, deficiencies of protein C, protein S, antithrombin III, and thrombomodulin.
💡
Conclusion & Impact:This article focuses on the clinical and the laboratory aspects of some of the inherited venous thrombotic disorders including the factor V Leiden, prothrombin G20210A mutation and protein S deficiency.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Up to date several hereditary disorders have been identified as prothrombic risk factors. The most common inherited thrombotic disorders include activated protein C resistance (factor V Leiden), prothrombin G20210A mutation, hyperhomocysteinemia, deficiencies of protein C, protein S, antithrombin III, and thrombomodulin. This article focuses on the clinical and the laboratory aspects of some of the inherited venous thrombotic disorders including the factor V Leiden, prothrombin G20210A mutation and protein S deficiency.

Özet

Bugüne kadar tromboz için risk faktörü olan birçok kalıtsal bozukluk tanımlanmıştır. Bunlardan en iyi bilinenler arasında aktive protein C rezistansı (faktör V Leiden), protrombin G20210A mutasyonu, hiperhomosisteinemi, protein C, protein S, antitrombin III ve trombomodülin eksikliği sayılabilir. Bu makalede üç olgu nedeni ile faktör V Leiden, protrombin G20210A mutasyonu ve protein S eksikliği ile ilgili bazı klinik ve laboratuvar bilgileri gözden geçirilecektir.

🔖

Cite This Article

KAYA, A., NUMANOĞLU, N., ÖNER, F., DOĞAN, R. (2022). Genetic risk factors of venous thromboembolism. Tüberküloz ve Toraks, Cilt: 51 - Sayı: 1, 60–69. https://ajindex.com/articles/619307

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Robetoyre RS, Rodgers GM. Update on selected inherited venous thrombotic disorders. Am J Hematol 2001; 68: 256-68
  2. Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis. Hum Genet 2001; 109: 369-84
  3. Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost 2001; 86: 395-403
  4. Souto JC, Almasy L, Borrell M, et al. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: The GAIT study. Genetic analysis of idiopathic thrombophilia. Am J Hum Genet 2000; 67: 1452-9
  5. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7
  6. Heeb MJ, Kojima Y, Greengard JS, Griffin JH. Activated protein C resistance: Molecular mechanisms based on studies using purified Gln506-factor V. Blood 1995; 85: 3405-11
  7. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4
  8. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thrombolism screenin. JAMA 1997; 277: 1305-7
  9. Akar N, Akar E, Dalgın G, et al. Frequency of Factor V (1691 G --> A) mutation in Turkish population. Thromb Haemost 1997; 78: 1527-8
  10. Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6
  11. Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7
  12. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22
  13. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-93
  14. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8
  15. Martinelli I, Landi G, Merati G, et al. Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost 1996; 75: 393-4. 16. de Moerloose P, Wutschert R, Heinzmann M, et al. Superficial vein thrombosis of lower limbs: Influence of factor V Leiden, factor II G20210A and overweight. Thromb Haemost 1998; 80: 239-41